NewsBenzingaGuggenheim mantiene il giudizio Buy su Regeneron Pharmaceuticals, alza il target di prezzo a $1100 Guggenheim mantiene il giudizio Buy su Regeneron Pharmaceuticals, alza il target di prezzo a $1100 Benzinga 2026.11.02 14:21 (GMT+0) Open on Benzinga Other news JP Morgan Maintains Neutral on Eastman Chemical, Lowers Price Target to $65 Why Is Rivian Stock Surging on Monday? JP Morgan Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $102 RBC Capital Maintains Sector Perform on FMC, Lowers Price Target to $7 Tilray Stock Rises As Cannabis Giant Raises EBITDA Outlook, Targets Restructuring Across Canada Here’s How Much You Would Have Made Owning Agnico Eagle Mines Stock In The Last 5 Years
